title: Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib.
abstract: To investigate the impact of the combination of early molecular and cytogenetic responses on the achievement of MR4.5, 228 newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib were categorized into 3-month and 6-month concordant optimal, discordant, concordant warning, and failure groups. Among them, 85.3% at 3 months and 78.1% at 6 months had concordant molecularly and cytogenetically defined responses. At both 3 and 6 months, patients with discordant, concordant warning and failure responses had similar 3-year MR4.5 rates, and all were significantly lower than the rate in patients with concordant optimal responses. Patients with concurrent 3-month and 6-month concordant optimal responses had a significantly higher 3-year MR4.5 rate than those with other responses, and 3-month and 6-month concurrent molecular optimal, but not cytogenetic optimal responses. Therefore, achieving concordant optimal molecular and cytogenetic responses at both 3 and 6 months with imatinib treatment are associated with MR4.5 achievement.
authors.affiliation: a Peking University People's Hospital, Peking University Institute of Hematology , Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China.
authors.forename: Ya-Zhen
authors.initials: YZ
authors.lastname: Qin
authors.affiliation: a Peking University People's Hospital, Peking University Institute of Hematology , Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Jiang
authors.affiliation: a Peking University People's Hospital, Peking University Institute of Hematology , Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China.
authors.forename: Yue-Yun
authors.initials: YY
authors.lastname: Lai
authors.affiliation: a Peking University People's Hospital, Peking University Institute of Hematology , Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China.
authors.forename: Hao
authors.initials: H
authors.lastname: Jiang
authors.affiliation: a Peking University People's Hospital, Peking University Institute of Hematology , Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China.
authors.forename: Hong-Xia
authors.initials: HX
authors.lastname: Shi
authors.affiliation: a Peking University People's Hospital, Peking University Institute of Hematology , Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China.
authors.forename: Xiao-Su
authors.initials: XS
authors.lastname: Zhao
authors.affiliation: a Peking University People's Hospital, Peking University Institute of Hematology , Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China.
authors.forename: Yan-Rong
authors.initials: YR
authors.lastname: Liu
authors.affiliation: a Peking University People's Hospital, Peking University Institute of Hematology , Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing , China.|b Peking-Tsinghua Center for Life Sciences , Beijing , China.
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D020732:Cytogenetic Analysis; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl
keywords: Chronic myeloid leukemia; cytogenetic response; imatinib; molecular response; molecular response of 4.5 (MR4.5)